ArticleRheumatology and therapy2026

Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States.

Christina Charles-Schoeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.